蔘笭白朮散이 Alzheimer's Disease 동물모델의 Astrocyte 활성화 및 Apoptosis에 미치는 영향

키워드

참고문헌 (52)

1. Blennow, K, "Alzheimer's disease", Lancet, 368(9533), pp.387~403 (2006)
2. Selkoe, D.J, "Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics", Annu Rev Pharmacol Toxicol, 43, pp.545~584 (2003)
3. Downey, D, "Pharmacologic management of Alzheimer disease", J Neurosci Nurs, 40(1), pp.55~59 (2008)
4. 錢鏡湖, "辨證奇問全書", pp.222~225 (1990), 甘地出版社
5. 陳士鐸, "石室秘錄", pp.125~ (1991), 中國中醫藥出版社
6. 洪元植, "精校黃帝內經素問", pp.37~ (1985), 東洋醫學硏究院
7. 朱震亨, "金櫃鉤玄", pp.306~307 (1992), 鼎談出版社
8. 張介賓, "張氏景岳全書", pp.610~611 (1978), 翰成社
9. 대한한방신경정신과학회, "한방신경정신의학", pp.311~320 (2007), 집문당
10. 陳師文, "中醫學大系", 太平惠民和劑局方, 9(147), pp.537~ (1990), 도서출판 鼎談
11. 신재용, "方藥合編解說", pp.37~ (1988), 성보사
12. 김현주, "加味補陽還五湯과 八味合聰明湯의 microglia 보호, 항산화 및 acetylcholinesterase 억제 효과", 동의신경정신과학회지, 19(2), pp.65~76 (2008), 대한한방신경정신과학회
13. 김헌일, "黃連淸心飮의 항산화 및 AChE 억제 효과에 관한 연구", 동의신경정신과학회지, 17(1), pp.1~16 (2006), 대한한방신경정신과학회
14. 이병훈, "紫河車 藥鍼이 βA로 誘導된 Alzheimer's Disease 病態 모델에 미치는 影響", 동의신경정신과학회지, 19(2), pp.41~64 (2008), 대한한방신경정신과학회
15. 최강욱, "天王補心丹 熱水抽出物, 超微細粉末劑形이 Alzheimer's Disease 病態 모델에 미치는 影響", 동의신경정신과학회지, 19(2), pp.77~94 (2008), 대한한방신경정신과학회
16. 서규태, "鹿茸大補湯이 β-amyloid로 誘導된 Alzheimer's Disease 病態 모델에 미치는 影響", pp.2007
17. 송호철, "加味蔘笭 白朮散 hexane세분획의 抗轉移 및 혈관형성억제작용에 대한 연구", 동의생리병리학회지, 15(6), pp.967~974 (2001), 대한동의병리학회
18. 김영진, "蔘笭白朮散의 Indomethacin 유도 위점막손상에 미치는 抗酸化效果", pp.1998
19. 송대섭, "蔘笭白朮散의 효능에 관한 실험적 연구", pp.1993
20. 許浚, "東醫寶鑑", pp.1158~ (1999), 법인문화사
21. Banker G, "Culturing nerve cells, second edition" (2002), MIT Press
22. 대한치매학회, "치매 임상적 접근", pp.23~24 (2006), 아카데미아
23. Bierer, L.M, "Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits", Journal of Neurochemistry, 64, pp.749~760 (1995)
24. 이광우, "임상신경학", pp.203~208 (2002), 고려의학
25. National Institute on Health, Progress Report on Alzheimer's Disease, "National Institute on Aging", ~ (1999)
26. acquevel, M, "Cytokines in neuroinflammation and Alzheimer's disease", Current Drug Targets, 5(6), pp.529~534 (2004)
27. Kuhl, D.E, "In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease", Neurology, 52(4), pp.691~699 (1999)
28. Mhatre, M, "Oxidative stress and neuroinflammation in Alzheimer's disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets", Journal of Alzheimers disease, 6(2), pp.147~157 (2004)
29. 안준익, "Beta-amyloid의 분자생물학", 한양의대학술지, 21(1), pp.11~16 (2001)
30. de Vente, J, "NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain , effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis", Eur J Neurosci, 12(2), pp.507~519 (2000)
31. Trabace, L, "Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease", J Pharmacol Exp Ther, 294(1), pp.187~194 (2000)
32. 李尙仁, "방제학", pp.278~ (1999), 영림사
33. 徐㚆霖, "脾胃理論與臨床", pp.28~36 (1990), 湖南科學技術出版社
34. 北京中醫學院中藥方劑敎硏組, "湯頭歌訣白話解", pp.56~57 (1995), 人民衛生出版社
35. 江克明, "簡明方劑辭典", pp.699~ (1989), 上海科學技術出版社
36. 이향중, "중의방제적약리급임상응용", pp.232~235 (1992), 人民衛生出版社
37. Selkoe, D.J, "Deciphering the genesis and fate of amyloid β-protein yields novel therapies for Alzheimer disease", J Clin Invest, 110(10), pp.1375~1381 (2002)
38. Kobayashi, K, "Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease", J Alzheimers Dis, 6(6), pp.623~632 (2004)
39. Paradis, S, "Astrocyte modulation of in vitro β-amyloid neurotoxicity", Glia, 46(3), pp.252~260 (2004)
40. Okada, S, "Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury", Nat Med, 12(7), pp.829~834 (2006)
41. Rich, T, "Apoptosis: the germs of death", Nat Cell Biol, 1(3), pp.69~71 (1999)
42. Vassar, R, "Caspase-3 cleavage of GGA3 stabilizes BACE: implications for Alzheimer's disease", Neuron, 54(5), pp.671~673 (2007)
43. Leung, L.S, "Cholinergic Activity Enhances Hippocampal Long-Term Potentiation in CA1 during Walking in Rats", J. Neurosci, 23, pp.9297~9304 (2003)
44. Weiss, C, "The M1 Muscarinic Agonist CI-1017 Facilitates Trace Eyeblink Conditioning in Aging Rabbits and Increases the Excitability of CA1 Pyramidal Neurons", J. Neurosci, 20, pp.783~790 (2000)
45. Oh, M.M, "Metrifonate Increases Neuronal Excitability in CA1 Pyramidal Neurons from Both Young and Aging Rabbit Hippocampus", J. Neurosci, 19, pp.1814~1823 (1999)
46. Raschetti, R, "Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials", PLoS Med, 4(11), pp.338~ (2007)
47. Villarroya, M, "An update on the pharmacology of galantamine", Expert Opin Investig Drugs, 16(12), pp.1987~1998 (2007)
48. During, M.J, "An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy", Science, 287(5457), pp.1453~1460 (2000)
49. Yee, A.S, "Convulsant and anticonvulsant effects on spontaneous CA3 population bursts", J Neurophysiol, 89(1), pp.427~441 (2003)
50. Wallenstein, G.V, "Functional transitions between epileptiform-like activity and associative memory in hippocampal region CA3", Brain Res Bull., 43, pp.485~493 (1997)
51. Leung, L.W, "Intrinsic membrane potential oscillations in hippocampal neurons in vitro", Brain Res, 553(2), pp.261~274 (1991)
52. House,r C.R, "Interneurons of the dentate gyrus: an overview of cell types, terminal fields and neurochemical identity", Prog Brain Res, 163, pp.217~232 (2007)

관련 논문AI추천